联合检测IL-2、IL-8和CA153在乳腺癌诊断中的价值研究

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the value of combined detection of interleukin-2(IL-2),interleukin-8(IL-8)and carbohydrate antigen 153(CA153)in the diagnosis of breast cancer.Methods Serum samples were collected from 65 patients with breast cancer,40 patients with benign breast tumor and 40 healthy subjects admitted to the Third Hospital of Nanchang City from June 2019 to December 2020.ELISA method and chemiluminescence method were used to detect serum levels of IL-2,IL-8 and CA153,respectively.In combination with IL-2,IL-8 and CA153,the receiver operating characteristic(ROC)curve was plotted in medcale software to calculate the diagnostic value and diagnostic efficacy of each indicator in the diagnosis of breast cancer.Results The level of IL-2 in the breast cancer group was lower than that in the benign breast tumor group and the healthy health group,and the level of IL-2 in the benign breast tumor group was lower than that in the healthy health group,the differences were statistically significant(P＜0.05).The levels of IL-8 and CA153 in the breast cancer group were higher than those in the benign breast tumor group and the healthy health group,and the level of IL-8 in the benign breast tumor group was higher than that in the healthy health group,the differences were statistically significant(P＜0.05).The area under ROC curve(AUC)of IL-2,IL-8 and CA153 detected by the combination was larger than that detected by each indicator alone.Conclusion The combined detection of serum IL-2,IL-8 and CA153 has a good value in the diagnosis of breast cancer.

Key words： Interleukin-2 Interleukin-8 Carbohydrate antigen 153 Breast cancer

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHU Chun-long
	ZHANG Yang-lin
	WAN Ren-jie
	DENG Yao
	LI Qing-xiang

Cite this article:

ZHU Chun-long,ZHANG Yang-lin,WAN Ren-jie, et al. Study on the value of combined detection of IL-2,IL-8 and CA153 in the diagnosis of breast cancer[J]. 中国当代医药, 2021, 28(26): 213-215转219.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I26/213

[1]	Hiensch AE，Mijwel S，Bargiela D，et al.Inflammation Mediates Exercise Effects on Fatigue in Patients with Breast Cancer[J].Med Sci Sports Exerc，2021，53（3）：496-504.
[2]	Fan Y，Chen X，Li H.Clinical value of serum biomarkers CA153，CEA，and white blood cells in predicting sentinel lymph node metastasis of breast cancer[J].Int J Clin Exp Pathol，2020，13（11）：2889-2894.
[3]	Martaindale SR.Breast MR Imaging：Atlas of Anatomy，Physiology，Pathophysiology，and Breast Imaging Reporting and Data Systems Lexicon[J].Magn Reson Imaging Clin N Am，2018，26（2）：179-190.
[4]	Tan R，Li H，Huang Z，et al.Neural Functions Play Different Roles in Triple Negative Breast Cancer （TNBC）and non-TNBC[J].Sci Rep，2020，10（1）：3065.
[5]	Deshmukh SK，Srivastava SK，Poosarla T，et al.Inflammation，immunosuppressive microenvironment and breast cancer：opportunities for cancer prevention and therapy[J].Ann Transl Med，2019，7（20）：593.
[6]	Wang R，Huang K.CCL11 increases the proportion of CD4+CD25+Foxp3+Treg cells and the production of IL-2 and TGF-β by CD4+T cells via the STAT5 signaling pathway[J].Mol Med Rep，2020，21（6）：2522-2532.
[7]	Mani A，Roda J，Young D，et al.A phase Ⅱtrial of trastuzumab in combination with low-dose interleukin-2 （IL-2）in patients（PTS）with metastatic breast cancer（MBC）who have previously failed trastuzumab[J].Breast Cancer Res Treat，2009，117（1）：83-89.
[8]	Chaurasiya S，Hew P，Crosley P，et al.Breast cancer gene therapy using an adenovirus encoding human IL-2 under control of mammaglobin promoter/enhancer sequences[J].Cancer Gene Ther，2016，23（6）：178-187.
[9]	Semushina SG，Aronov DA，Moiseeva EV.Local Interleukin-2 Immunotherapy of Breast Cancer：Benefit and Risk in a Spontaneous Mouse Model[J].Pathol Oncol Res，2019，25（3）：945-951.
[10]	杨青，张香梅.IL-8 及其受体在肿瘤进展与治疗中的研究进展[J].肿瘤防治研究，2019，46（1）：87-90.
[11]	王群拴，黎小花.核磁共振结合血清肿瘤标志物及细胞因子检测在乳腺癌诊断中的应用价值研究[J].陕西医学杂志，2019，48（10）：1295-1297.
[18]	Nicolini A，Ferrari P，Rossi G.Mucins and Cytokeratins as Serum Tumor Markers in Breast Cancer[J].Adv Exp Med Biol，2015，867：197-225.
[12]	Singh JK，Simoes BM，Howell SJ，et al.Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells[J].Breast Cancer Res，2013，15（4）：210.
[13]	Tiainen L，，Luukkaala T，et al.Low Plasma IL-8 Levels During Chemotherapy Are Predictive of Excellent Long-Term Survival in Metastatic Breast Cancer[J].Clin Breast Cancer，2019，19（4）：e522-e533.
[14]	Fernando A，Jayarajah U，Prabashani S，et al.Incidence trends and patterns of breast cancer in Sri Lanka：an analysis of the national cancer database[J].BMC Cancer，2018，18（1）：482.
[15]	Lian M，Zhang C，Zhang D，et al.The association of five preoperative serum tumor markers and pathological features in patients with breast cancer[J].J Clin Lab Anal，2019，33（5）：e22875.
[16]	Song X，Liang B，Wang C，et al.Clinical value of color Doppler ultrasound combined with serum CA153，CEA and TSGF detection in the diagnosis of breast cancer[J].Exp Ther Med，2020，20（2）：1822-1828.
[17]	Li J，Liu L，Feng Z，et al.Tumor markers CA15-3，CA125，CEA and breast cancer survival by molecular subtype：a cohort study[J].Breast Cancer，2020，27（4）：621-630.